Welcome to our dedicated page for Vaccinex news (Ticker: VCNX), a resource for investors and traders seeking the latest updates and insights on Vaccinex stock.
Vaccinex, Inc. reports developments as a clinical-stage biotechnology company focused on investigational antibody therapies for neurodegenerative disease and cancer. Its lead program, pepinemab, is an anti-SEMA4D antibody being developed for Alzheimer’s disease and other neurological indications, with additional clinical work in cancer, including head and neck cancer and melanoma immunotherapy settings.
Company news commonly covers pepinemab clinical data presentations, financial results, development financing, and corporate updates tied to listing status and OTC quotation. Vaccinex also reports activity involving its ActivMAb® platform, which uses viral display of complex antigens to support antibody discovery collaborations and project agreements.
Vaccinex, Inc. (Nasdaq: VCNX), a biotechnology firm focused on cancer and neurodegenerative disease therapies, announced its selection for a poster presentation at the 18th Annual PEGS Boston Conference from May 2-6, 2022. The presentation will showcase their ActivMAb technology, which enables efficient expression of complex transmembrane receptors critical for drug discovery. This groundbreaking platform successfully identifies antibodies against targets like SARS-CoV2 and chemokine receptor CXCR4. Details will be accessible on their website starting May 2 at 3:50 PM EST.
Vaccinex, Inc. (Nasdaq: VCNX) reported positive developments in its ongoing clinical trials for pepinemab in oncology and neurodegenerative diseases. The Phase 1b segment of the KEYNOTE-B84 study in head and neck cancer showed two complete responses among three initial patients. Enrollment is ongoing for both the KEYNOTE-B84 and SIGNAL-AD trials, with topline data expected in 2023. Financially, Vaccinex ended 2021 with $8.6 million in cash, reflecting a decrease from $10.6 million in 2020. The comprehensive loss for 2021 was $22.4 million, an improvement from $28.9 million in the previous year.
Vaccinex, Inc. (Nasdaq: VCNX) announced its selection for a poster presentation at the 2022 American Association for Cancer Research Meetings, showcasing the phase 1b segment of the KEYNOTE-B84 study. This study evaluates pepinemab in combination with KEYTRUDA for patients with recurrent or metastatic head and neck cancer. The presentation is scheduled for April 11, 2022, featuring abstract CT111 by VP Clinical Science Terrence Fisher. Vaccinex holds global rights to pepinemab, which aims to improve tumor immunity and shows promise in ongoing clinical trials.
Vaccinex, Inc. (Nasdaq: VCNX) announced a poster presentation for its research on combination immunotherapy and HTT-lowering in humanized HD mice at the 17th Annual HD Therapeutics Conference on March 2, 2022. The presentation, led by Dr. Amber Southwell, will explore the efficacy of pepinemab in treating Huntington's disease by inhibiting semaphorin 4D (SEMA4D). The conference serves as a platform for advancing research in neurodegenerative diseases. Detailed presentation information and links are available on the company’s website.
Vaccinex announces a stock purchase agreement on January 27, 2022, with existing and new investors for a private placement of 5,945,943 shares at $1.11 per share, yielding approximately $6.6 million. This funding is part of a total of $10.1 million in new equity financing for January 2022. The proceeds will support the development of pepinemab, its lead drug candidate for cancer and neurodegenerative diseases. The placement is expected to close by January 31, 2022, and includes a registration rights agreement with investors.
Vaccinex, a clinical-stage biotechnology firm, announced positive interim results from the Phase Ib segment of the KEYNOTE-B84 study, featuring its drug pepinemab combined with Merck's KEYTRUDA for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Of three patients, two achieved a complete response (CR), despite low PD-L1 biomarker levels. The recommended dose of pepinemab was well tolerated, allowing the continuation of treatment.
Vaccinex plans to expand the trial, enrolling up to an additional 62 patients, and aims to share further findings at a medical conference in 2022.
Vaccinex, Inc. (Nasdaq: VCNX) announced positive interim safety data from the Phase 1b segment of the KEYNOTE B84 study, evaluating the combination of pepinemab and Keytruda in advanced head and neck cancer patients. The safety run-in phase confirmed that pepinemab (20 mg/kg) and Keytruda (200 mg Q3W) were well tolerated, paving the way for the Phase 2 expansion segment, which will enroll up to 62 subjects. This study aims to assess the Objective Response Rate (ORR) and other key metrics, with interim results expected in the second half of 2022.
Vaccinex, Inc. (Nasdaq: VCNX) has announced that Dr. Elizabeth Evans will present a Phase 1/2 study on pepinemab in combination with pembrolizumab for advanced head and neck cancer at the SITC Annual Meeting from November 12-14, 2021. The presentation, Poster #434, will highlight the potential of pepinemab in enhancing treatment efficacy. The poster will be showcased in-person and virtually, with virtual access available until January 9, 2022. Vaccinex aims to leverage its unique drug discovery platform to expand its therapeutic pipeline, particularly in cancer and neurodegenerative diseases.
Vaccinex, Inc. (Nasdaq: VCNX) announces a live presentation by Terrence Fisher, Ph.D., at the Clinical Trials on Alzheimer's Disease Meeting in Boston on November 11, 2021. The presentation will focus on the potential of pepinemab, a SEMA4D-blocking antibody, as a novel treatment for neurodegenerative diseases, supported by clinical proof of concept in Huntington's Disease. Vaccinex aims to leverage its proprietary ActivMAb® platform for future drug development. Further details about the presentation can be found on the company’s website.
Vaccinex, Inc. (Nasdaq: VCNX) has launched clinical trials for its drug pepinemab, targeting advanced recurrent head and neck cancer and Alzheimer’s disease. The Phase 1b/2 trial in head and neck cancer will assess the combination with KEYTRUDA® and aims to enroll 65 subjects, with results expected in H2 2022. The Alzheimer’s study has begun enrollment for 40 subjects, with topline data anticipated in late 2022 or early 2023. Financially, R&D expenses decreased significantly to $3.6 million from $7.3 million year-over-year, while cash reserves increased to $13.8 million.